Objective: To describe the clinical use of URO17®, a noninvasive, urine-based immunocytochemistry assay targeting Keratin 17 (K17), as an adjunct to conventional diagnostic methods for urothelial carcinoma. Here, KRT17 is linked to urothelial carcinoma.